LiverLearning®: 2019 Webinar: HCV Treatment in Patients with IDU
Injection Drug Use (IDU) remains the leading risk factor for HCV. Unfortunately, significant obstacles limit every aspect of the HCV care cascade in this population.
Erratum
21 May 2019
Issue Information
21 May 2019
Issue Information
21 May 2019
Issue Information
21 May 2019
Erratum
21 May 2019
Clinical Utility of a Risk‐Adapted Protocol for the Evaluation of Coronary Artery Disease in Liver Transplant Recipients
Mario Romero‐Cristóbal, Teresa Mombiela, Aranzazu Caballero, Ana Clemente, Ainhoa Fernández‐Yunquera, Fernando Diaz‐Fontenla, Diego Rincón, Cristina Ripoll, Javier Bermejo, María‐Vega Catalina, Ana‐María Matilla, Luis Ibáñez‐Samaniego, José Pérez‐Peña, José‐Ángel López‐Baena, Benjamín Díaz‐Zorita, Francisco Fernández‐Avilés, M. Magdalena Salcedo, Rafael Bañares – 20 May 2019 – The prevalence and management of coronary artery disease (CAD) in liver transplantation (LT) candidates are not well characterized.